- Home
- DHF vs ARCT Comparison
DHF vs ARCT Comparison
Compare DHF & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHF | ARCT |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.2M | 163.4M |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DHF | ARCT |
|---|---|---|
| Price | $2.40 | $7.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $24.11 |
| AVG Volume (30 Days) | 265.4K | ★ 506.3K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.32 | $5.50 |
| 52 Week High | $2.63 | $24.14 |
Technical Indicators
Market Signals| Indicator | DHF | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 66.41 |
| Support Level | $2.38 | $6.70 |
| Resistance Level | $2.42 | $7.98 |
| Average True Range (ATR) | 0.03 | 0.39 |
| MACD | 0.00 | 0.25 |
| Stochastic Oscillator | 73.03 | 99.78 |
Price Performance
Historical ComparisonAbout DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.